Enzymatica Q4: Important year ahead and an expected rights issue - Redeye

Redeye provides an update in relation to Enzymatica’s Q4 2023 report. The report came in a bit under our expectations. Moreover, the company carries out a rights issue of SEK27.4m, which aligns with our estimate. Based on the report, we make some changes in our forecasts; however, the changes do not render an updated fair value range, including a base case of SEK6.

Länk till analysen i sin helhet: https://www.redeye.se/research/981865/enzymatica-q4-important-year-ahead-and-an-expected-rights-issue?utm_source=finwire&utm_medium=RSS